Atwood & Palmer Inc. maintained its position in Amgen Inc. (NASDAQ:AMGN) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,181 shares of the medical research company’s stock at the close of the 2nd quarter. Atwood & Palmer Inc.’s holdings in Amgen were worth $1,926,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of AMGN. Canada Pension Plan Investment Board lifted its holdings in shares of Amgen by 65.7% during the 2nd quarter. Canada Pension Plan Investment Board now owns 1,706,261 shares of the medical research company’s stock worth $293,869,000 after acquiring an additional 676,300 shares during the last quarter. Skandinaviska Enskilda Banken AB publ bought a new stake in shares of Amgen during the 1st quarter worth $110,402,000. Swiss National Bank lifted its holdings in shares of Amgen by 26.5% during the 1st quarter. Swiss National Bank now owns 2,636,008 shares of the medical research company’s stock worth $432,490,000 after acquiring an additional 551,600 shares during the last quarter. Bank of Nova Scotia lifted its holdings in shares of Amgen by 414.4% during the 1st quarter. Bank of Nova Scotia now owns 601,862 shares of the medical research company’s stock worth $98,747,000 after acquiring an additional 484,868 shares during the last quarter. Finally, First Eagle Investment Management LLC bought a new stake in shares of Amgen during the 2nd quarter worth $71,081,000. 78.20% of the stock is owned by institutional investors.

A number of analysts have recently issued reports on AMGN shares. BMO Capital Markets reaffirmed a “market perform” rating and set a $198.00 price objective on shares of Amgen in a report on Thursday, October 26th. Cann reaffirmed a “buy” rating on shares of Amgen in a report on Monday, August 28th. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and set a $203.00 price objective on shares of Amgen in a report on Thursday, September 7th. Mizuho reaffirmed a “buy” rating and set a $198.00 price objective (up from $183.00) on shares of Amgen in a report on Thursday, September 28th. Finally, Zacks Investment Research downgraded shares of Amgen from a “buy” rating to a “hold” rating in a report on Monday, October 16th. Thirteen investment analysts have rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $190.03.

In related news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $171.58, for a total transaction of $261,659.50. Following the sale, the executive vice president now owns 57,631 shares of the company’s stock, valued at $9,888,326.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Carbonnel Francois De sold 4,000 shares of the business’s stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total transaction of $694,440.00. The disclosure for this sale can be found here. Insiders have sold 7,050 shares of company stock worth $1,239,673 in the last three months. 0.19% of the stock is currently owned by insiders.

Shares of Amgen Inc. (NASDAQ AMGN) opened at $170.00 on Friday. Amgen Inc. has a 52 week low of $138.83 and a 52 week high of $191.10. The company has a debt-to-equity ratio of 1.05, a quick ratio of 5.72 and a current ratio of 6.07. The company has a market cap of $123,960.00, a PE ratio of 13.52, a P/E/G ratio of 2.46 and a beta of 1.37.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Wednesday, October 25th. The medical research company reported $3.27 EPS for the quarter, topping the consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The business had revenue of $5.77 billion for the quarter, compared to analyst estimates of $5.75 billion. During the same quarter in the previous year, the firm posted $3.02 earnings per share. Amgen’s quarterly revenue was down .7% on a year-over-year basis. analysts expect that Amgen Inc. will post 12.66 EPS for the current fiscal year.

Amgen announced that its board has approved a stock repurchase program on Wednesday, October 25th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical research company to buy shares of its stock through open market purchases. Shares buyback programs are usually a sign that the company’s board of directors believes its stock is undervalued.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Friday, November 17th will be paid a dividend of $1.15 per share. This represents a $4.60 annualized dividend and a yield of 2.71%. The ex-dividend date of this dividend is Thursday, November 16th. Amgen’s payout ratio is currently 41.55%.

ILLEGAL ACTIVITY WARNING: “Atwood & Palmer Inc. Has $1,926,000 Holdings in Amgen Inc. (AMGN)” was first reported by Daily Political and is owned by of Daily Political. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://www.dailypolitical.com/2017/11/18/atwood-palmer-inc-has-1926000-holdings-in-amgen-inc-amgn.html.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.